Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22917996 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL8208823 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL13698145 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL14255652 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL14255638 | 0.91 | SLC6A4 (0.39) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL4180226 | 0.84 | DRD2 (0.40) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL14124614 | 0.84 | DRD2 (0.40) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL4191008 | 0.83 | DRD2 (0.39) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL19261800 | 0.83 | DRD2 (0.39) | SLC6A3SLC6A4DRD2 | |
| SCHEMBL13698146 | 0.83 | DRD2 (0.39) | SLC6A3SLC6A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A3 92/4885SLC6A4 221/4885DRD2 35/4885 |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | SLC6A3 982/4885SLC6A4 2230/4885DRD2 795/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A3 92/4885SLC6A4 221/4885DRD2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.